Back to top
more

Owens & Minor (OMI)

(Delayed Data from NYSE)

$11.80 USD

11.80
1,273,040

-0.20 (-1.67%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $11.51 -0.29 (-2.46%) 7:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Owens & Minor (OMI) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 22.22% and 1.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 3.64% and 3.60%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Owens & Minor (OMI) Stock?

by Zacks Equity Research

Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Owens & Minor (OMI) Stock?

by Zacks Equity Research

Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.

Owens & Minor (OMI) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 12.50% and 3.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?

by Zacks Equity Research

Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.

Best Value Stocks to Buy for May 9th

by Zacks Equity Research

GTX, PLTK and OMI made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 9, 2023.

Owens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 155.56% and 4.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Owens & Minor (OMI) Misses Q4 Earnings Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of -28.21% and 6.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AdaptHealth Corp. (AHCO) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AdaptHealth Corp. (AHCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Owens & Minor (OMI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Owens & Minor (OMI) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 5.13% and 3.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

by Zacks Equity Research

Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Owens & Minor (OMI) Q3 Earnings Expected to Decline

by Zacks Equity Research

Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Owens & Minor (OMI) Q2 Earnings Meet Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 0% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Owens & Minor (OMI) Q2 Earnings Expected to Decline

by Zacks Equity Research

Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Owens & Minor (OMI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.

Owens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 24.68% and 3.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Is GN Store Nord (GNNDY) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up

by Zacks Equity Research

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.

Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

In Q1, Chemed's (CHE) VITAS revenue decline was primarily the result of a 4.1% decline in days of care.

Earnings Preview: Owens & Minor (OMI) Q1 Earnings Expected to Decline

by Zacks Equity Research

Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Philips' (PHG) Q1 Earnings Down Y/Y on Supply Chain Constraints

by Zacks Equity Research

Koninklijke Philips' (PHG) Q1 top- and bottom-line results reflect negative impact of supply chain constraints and consequences of the Respironics field action.

Here's Why You Should Retain Integra (IART) Stock For Now

by Zacks Equity Research

Investors are optimistic about Integra (IART), given the strength in its CSS arm and notable product launches.